CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.

This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach. The study will collect data from participants via the questionnaire developed by the research team. This study will be conducted in two stages. Stage 1 is the study design phase (i.e., qualitative stage and questionnaire development), which includes the development of the questionnaire, identification of key attributes and levels for the Discrete Choice Experiment (DCE), creation of hypothetical patient profiles to explore high-risk factors in physician decision-making beyond the DCE, as well as questionnaire programming, internal review, pilot testing, revisions, and finalization. Stage 2 involves the implementation of the quantitative survey using the finalized questionnaire and the subsequent data analysis to generate insights into treatment preferences.

Inclusion Criteria: The following inclusion criteria must be met in order to be enrolled in the stage 1: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter Physician: * Provide informed consent * Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals * Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month * Holding the title of associate chief physician or higher The following inclusion criteria must be met in order to be enrolled in the stage 2: Patient: * Provide informed consent * 18 years or older * Diagnosed with stage IV NSCLC * Currently receiving or previously received 1L EGFR-TKI treatment * Without communication barrier * Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter Physician: * Provide informed consent * Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals * Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month * Holding the title of attending physician or higher Exclusion Criteria: Not applicable.